Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Feb 27, 2022; 14(2): 107-119
Published online Feb 27, 2022. doi: 10.4240/wjgs.v14.i2.107
Table 1 Demographic data of Mirizzi syndrome patients, n (%), (mean ± SD), (range and median)
Category

Male/Female34/32
Age (yr)48.1 ± 15.0, 18-83, 47
Admission route (Emergency/Outpatient)48/18
Previous admissions2.24 ± 0.96, 1-3, 3
Months from discovery of gallstone to this admission17.8 ± 4.51, 9-22, 21
Confirmed episodes of abdominal pain2.15 ± 1.04, 1-6, 2
Total bilirubin (μmol/L)≤ 2831 (47.0%)
28-5627 (40.9%)
> 568 (12.1%)
Postoperative pathologicalresults ofgallbladderAcute inflammation24 (36.4%)
Acute inflammation and gangrene8 (12.1%)
Acute suppurative inflammation9 (13.6%)
Chronic inflammation12 (18.2%)
Chronic suppurative inflammation5 (7.6%)
Xanthogranuloma8 (12.1%)
Preoperative PTCD6 (9.1%)
Preoperative treatment time (d)6.35 ± 3.28, 2-20, 6
Postoperative treatment time (d)7.36 ± 3.66, 3-19, 6.5
Total hospitalization time (d)13.76 ± 5.41, 6-31, 13
Hospitalization cost (CNY Yuan)24549 ± 6536, 13596-40815, 23044
Table 2 Diagnosticclues of Mirizzi syndrome by ultrasound scan and magnetic resonance imaging/magnetic resonance cholangiopancreatography in different cases
Imaging examination

Type I
Type II
Type III
Statistics
Total bilirubin (μmol/L)
Statistics
≤ 28
28-56
> 56
USS+1086χ2 = 12.00; P = 0.0021194χ2 = 0.760; P = 0.684
-326420184
MRI/MRCP+341410χ2 = 5.202; P = 0.07423278χ2 = 10.28; P = 0.006
-800800
Table 3 Effects of Csendes classification on surgical methods, operative time, bleeding volume, hospitalization time and cost (n = 66), (mean ± SD), (range, median)

Type I
Type II
Type III
Type IV
Statistics
n (%)42 (63.64%)14 (21.21%)10 (15.15%)0
Total bilirubin (μmol/L)≤ 282920-χ2 = 51.42; P = 0.000
28-5613113-
> 56017-
Surgical methodsLC29620-χ2 = 29.91; P = 0.000
LC convert to OC2320-
LC convert to OC + BDER + T-tube71,24383-
OC0120-
OC + BDER + T-tube41,2023-
Hospitalization time (d)12.8 ± 4.8; 6-25, 12.515.1 ± 6.2; 8-26, 13.515.9 ± 6.1; 8-31, 15-F = 1.981; P = 0.146
Treatment cost (CNY Yuan)23037 ± 5522; 13596-40815, 2196324916 ± 7146; 15108-36557, 2359330387 ± 6865; 17161-40568, 28624-F = 5.909; P = 0.004
Operative time (minutes)154.4 ± 91.1; 50-395, 122.5230.4 ± 133.7; 80-480, 175219.0 ± 122.2; 95-520, 177.5-F = 3.486; P = 0.037
Bleeding volume (mL)96.6 ± 81.5; 20-340, 60191.4 ± 123.3; 30-390, 180163.5 ± 114.3; 25-400, 140-F = 5.919; P = 0.004
Table 4 Intraoperative data and technical details (n = 66)
Category
n = 66
Final surgical approach3-port laparoscopic surgery24, 36.4%
4-port laparoscopic surgery11, 16.7%
Right subcostal incision31, 46.9%
Maximum diameter of stone (cm)2.15 ± 1.17, 0.5-6, 2
Fistula size (mm)Longitudinal diameter4.1 ± 1.0, 2-6, 4
Transverse diameter4.5 ± 1.4, 2-8, 4
Diameter of extra hepatic bile duct (mm)Maximum 14 ± 2.8, 10-22, 14
Minimum 8.4 ± 1.8, 6-12, 8
Iatrogenic BDI11, 16.7% (11 in type I)
Retrograde resection of gallbladder36, 54.5%
BDER (35, 53%)Simple suture repair21, 31.8% (11 in type I, 10 in type II)
STC and repair using gallbladder wall14, 21.2% (4 in Type II,10 in type III)
T-tube (25, 37.9%) (14-22 Fr, 18 Fr)Transfistula 3 (in type III)
Transbiliary incision 22
Cholangiography (25, 37.9%)Trans-PTCD61
Trans-T-tube25
Choledochoscopy (25, 37.9%)Trans-fistula3
Trans-cystic duct2
Trans-biliary incision20
Operative time (min)180 ± 110, 50-520, 140
Bleeding volume (mL)127 ± 104, 87.5, 20-400
Table 5 Postoperative complications (n = 66)
Postoperative complications
n (%)
Incision infection7 (10.6)
Bile leakage9 (13.6)
Bloody drainage4 (6.1)
Cholangitis5 (7.6)
Abnormal liver function14 (21.2)
Biliary stricture1 (1.5)
Residual or recurrent stone5 (7.6)
Pneumonia3 (4.5)
Gastrointestinal dysfunction7 (10.6)